Salix Pharmaceuticals Ltd, Valeant Pharmaceuticals deal

Valeant will acquire Salix for $158 per share in cash, or about $14.5 billion. The price is $0.15 above Salix’s share price on Feb. 20, before the deal was announced, and a 3.7% premium to its close of $150.74 on Feb. 19, before rumors of a deal bumped up the stock. Both companies’ boards approved the deal, which is expected to close in 2Q15. ...